{
    "clinical_study": {
        "@rank": "82514", 
        "brief_summary": {
            "textblock": "To determine the safety and pharmacokinetics of L-ofloxacin (RWJ 25213) in patients with HIV\n      infection."
        }, 
        "brief_title": "A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have the following:\n\n        HIV infection.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Active opportunistic infection or neoplasm.\n\n          -  High likelihood of death during study.\n\n          -  Significant ophthalmologic, renal, hepatic, cardiovascular, hematologic, neurologic,\n             psychiatric,respiratory, or metabolic disease.\n\n          -  Donation of > 1 unit blood or acute loss of blood within one month of study entry.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of opportunistic infection.\n\n          -  Previous allergic reaction to ciprofloxacin, norfloxacin, or any other quinolone.\n\n        Prior Medication:\n\n        Excluded:\n\n        Use of any investigational agent within 7 days of entry into study. Use of any medication\n        within 3 days prior to entry (7 days for AZT). Alcohol or drug abuse."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002249", 
            "org_study_id": "105A/B", 
            "secondary_id": [
                "K90-086", 
                "K90-024"
            ]
        }, 
        "intervention": {
            "intervention_name": "Levofloxacin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Infective Agents", 
                "Ofloxacin"
            ]
        }, 
        "keyword": [
            "Anti-Infective Agents, Quinolone", 
            "Ofloxacin", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Raritan", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "088690602"
                }, 
                "name": "R W Johnson Pharmaceutical Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "8031049", 
            "citation": "Goodwin SD, Gallis HA, Chow AT, Wong FA, Flor SC, Bartlett JA. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1994 Apr;38(4):799-804."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002249"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "R W Johnson Pharmaceutical Research Institute", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 1991"
    }, 
    "geocoordinates": {
        "R W Johnson Pharmaceutical Research Institute": "40.57 -74.633"
    }
}